Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 106,113

Document Document Title
WO/2015/079241A1
The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use as an anticonvulsant and/or seizure suppressant, in particular in the treatment or prevention of (e.g. juvenile)epilepsy.  
WO/2015/079692A1
[Problem] To provide a compound having a formyl peptide receptor-like 1 (FPRL1) agonist effect. [Solution] The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The...  
WO/2015/077246A1
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurologica...  
WO/2015/075942A1
 The present invention provides a vesicle for delivering a drug to the brain, a conjugate, a composition containing same, and a method for administering same. A composition for administration to a subject according to a dosing regimen,...  
WO/2015/077611A1
Disclosed are substituted (4'-hydroxylphenyl)cycloalkane compounds and there use as selective agonists of the estrogen receptor beta isoform (ΕΚβ). The disclosed compounds may be formulated as pharmaceutical compositions and administe...  
WO/2015/074494A1
Uses of ginsenoside-Rg3 in preparing medicine or health care products for preventing and treating brain dementia. The medicine or health care products comprise external preparation, oral preparation and injection containing ginsenoside-Rg3.  
WO/2015/076589A1
The present invention relates to a nerve-cell-regenerating pharmaceutical composition containing Vax protein as an active ingredient, and, more specifically, the Vax protein can advantageously be used as a nerve-cell-regenerating pharmac...  
WO/2015/074137A1
The disclosure provides methods of treatment of ocular inflammation or neuropathic pain in a subject in need thereof, comprising administering to the subject in need thereof a CB2 target agent, a cannabimimetic agent (such as a non-psych...  
WO/2015/074114A1
A method for minimising or preventing the induction of stress-related or stress- induced inappetance or inanition in an animal selected for a marketing or management practice.  
WO/2015/075515A1
The object of the present invention is a drug for the therapeutic treatment of tumours, also usable as diagnostic agent and therapeutic agent for the Alzheimer's disease. Such drug comprises a copper-64 radioisotope in its salt form, sai...  
WO/2015/077780A1
Provided herein are synthetic analogs of withanolide natural products of formula (I), wherein R1-R4 are as defined herein, and their pharmaceutical uses in treating neurodegenerative diseases.  
WO/2015/075288A1
The invention pertains to the field of the study of apoptosis, especially the field of the prognosis and monitoring of diseases wherein apoptosis occurs. Concretely, the invention relates to a method for isolating apoptotic bodies from a...  
WO/2015/075155A1
The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of obsessions and/or compulsions in an individual.  
WO/2015/075003A1
The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a preparation for the reduction of both intra-operative and post-operative pain caused by castration of male pigl...  
WO/2015/076286A1
Provided is an ephedra extract stripped of ephedrine alkaloids, i.e., an ephedra extract from which ephedrine alkaloids have been removed, and a method for producing an ephedra extract stripped of ephedrine alkaloids. Also provided are a...  
WO/2015/075025A1
The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, ...  
WO/2015/076325A1
[Problem] To provide a novel glycyrrhetinic acid derivative. [Solution] A glycyrrhetinic acid derivative represented by formula (1). (1)  
WO/2015/077640A1
Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are di...  
WO/2015/076340A1
An injectable composition which comprises (1) a methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1 ,4]benzodiazepine-4-yl]propanoate or a salt thereof as an active ingredient and (2) one type or more of an additive selec...  
WO/2015/077535A3
The invention relates to dihydroorate dehydrogenase (DHODH) inhibitors useful for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis.  
WO/2015/075082A1
The present invention deals with compounds of formula (I) which are novel uncharged reactivators of human acetylcholinesterase, pharmaceutical compositions comprising said compounds, and their use for reactivating human acetylcholinester...  
WO/2015/076631A1
The present invention provides a composition containing malt extracts as an active ingredient. The composition of the present invention exhibits an effect of promoting longitudinal bone growth.  
WO/2015/073803A1
This invention relates to compositions and methods for the therapy and diagnosis of neurodegenerative or neuromuscular disorders. More particularly, this invention relates to use of anaplerotic agents for treating, preventing, or delayin...  
WO/2015/073763A1
The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  
WO/2015/073767A1
The invention provides compounds of Formula (I): [INSERT CHEMICAL STRUCTURE HERE] and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  
WO/2015/073867A1
Described herein are recombinant polynucleotide-binding polypeptides, recombinant fusion proteins made with the described polynucleotide-binding polypeptides, methods of using the described recombinant polynucleotide-binding polypeptides...  
WO/2015/071178A1
The present invention relates to compounds of general formula (I), wherein R1 is hydrogen; R2 is hydrogen, lower alkyl, benzyl, lower alkyl substituted by hydroxy or is cycloalkyl optionally substituted by cyano; or R1 and R2 form togeth...  
WO/2015/073514A1
Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.  
WO/2015/073441A1
Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercill...  
WO/2015/073967A1
Disclosed embodiments are related to compositions comprising novel piperazine compounds suitable for administration to a mammal for treatment of dopaminergic diseases and methods of administering the same.  
WO/2015/072544A1
 Provided are a novel agent for treating autoimmune disease containing CTRP3, and a novel method for treating autoimmune disease including the administration of an agent for treating autoimmune disease containing CTRP3 to a subject req...  
WO/2015/072667A1
The present invention relates to a composition for alleviating oxidative stress-induced cranial nervous system diseases, containing corn silk-derived maysin as an active ingredient and, more particularly, to a pharmacological composition...  
WO/2015/073444A1
The present application in one aspect provides methods and compositions that are fine- tuned to modulate brain and peripheral serotonin levels, which in turn would lead to prevention and treatment of various diseases associated with a re...  
WO/2015/073515A1
Disclosed herein are nutritional compositions for pregnant or lactating mothers, pre-term and term infants, toddlers and children which include natural vitamin E, a long chain polyunsaturated fatty acid (LC-PUFA) and a cartenoid such as ...  
WO/2015/073736A1
The present invention provides compositions and methods of using α2 adrenergic receptor agonists as treatments for ADHD. The α2 adrenergic receptor agonist for use with these methods is a benzimidazole derivative, and may be specifical...  
WO/2015/069115A1
The invention related to methods of treatment of an individual suffering from or at risk of suffering from a selective estrogen-receptor modulator (SERM) induced adverse drug reaction. The invention additionally relates to a pharmaceutic...  
WO/2015/070156A1
The invention relates to a rapidly disintegrating oral dosage form that contains a drug/polymer solid solution and methods of using the oral dosage form.  
WO/2015/067923A1
Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.  
WO/2015/069110A1
The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic...  
WO/2015/067773A1
The present invention relates to an ethanol-based plant macerate which includes the following active agents obtained from plant extracts: eugenol, caffeine and/or theine, piperine, theobromine, gingerol and menthol. The ethanol-based pla...  
WO/2015/069809A1
This disclosure relates to a method of treating a neurological disorder by administering an antidepressant compound and dextromethorphan to a human being in need thereof. This method may be useful for human beings that are extensive meta...  
WO/2015/069752A9
The invention provides compositions and methods a) for increasing or stimulating the release of other transmitters (excitatory amino acids, inhibitor amino acids and biogenic amines) in the central nervous system (CNS) or the brain, or m...  
WO/2015/069833A1
Provided herein are genetic markers for predicting response to antipsychotic treatment. Genotyping of the disclosed SNPs can be used to predict response to antipsychotic drugs in patients suffering from schizophrenia. There is provided m...  
WO/2015/069086A1
A composition of the present invention containing a fraction of Panax ginseng or ginsenoside separated therefrom has an effect of activating sirtuins, and thus can be useful for medicines, cosmetics, and foods for preventing or treating ...  
WO/2015/069752A1
The invention provides compositions and methods a) for increasing or stimulating the release of other transmitters (excitatory amino acids, inhibitor amino acids and biogenic amines) in the central nervous system (CNS) or the brain, or m...  
WO/2015/070003A1
The present invention relates to the use of a pharmaceutical composition comprising a pyrethroid compound for inhibiting unwanted eye movement and for treating eye movement disorders, such as, but not limited to, nystagmus. The invention...  
WO/2015/069140A1
The invention relates to medicine and the chemical and pharmaceutical industry and concerns agents that exhibit nootropic and neuromodulatory activity. The present pharmaceutical composition in tablet form, which exhibits nootropic and n...  
WO/2015/069736A1
Enhanced methods for the generation of medial ganglionic eminence (MGE) cells from pluripotent stem cells are provided that involve an additional step of contacting the cells with an activator of FGF8 signaling while differentiating Pax6...  
WO/2015/067130A1
(S)-4-hydroxyl-2-keto-1-piracetam crystal form III (called (s)- oxiracetam crystal form III for short) has diffraction peaks at diffraction angles 2θ, wherein the diffraction angles 2θ are equal to 10.54°, 13.70°, 14.44°, 15.60°, 1...  
WO/2015/069970A1
Hybrid compounds of curcumin and melatonin as neuroprotectants are provided. The hybrid compounds are useful for the treatment and/or prevention of Alzheimer's disease (AD), as well as other neurodegenerative diseases. The hybrid compoun...  

Matches 251 - 300 out of 106,113